EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

Marina Salmón, Ruth Álvarez-Díaz, Coral Fustero-Torre, Oksana Brehey, Carmen G Lechuga, Manuel Sanclemente, Fernando Fernández-García, Alejandra López-García, María Carmen Martín-Guijarro, Sandra Rodríguez-Perales, Emily Bousquet-Mur, Lucía Morales-Cacho und 10 weitere

Journal of Clinical Investigation · 03.04.2023 · 133 (7)

DOI: 10.1172/jci164413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.04.2023. Verfasst von Marina Salmón und 21 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Oncology Group, Molecular Oncology Program. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 European Research Council, Ministerio de Ciencia e Innovación, Comunidad de Madrid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRASG12C inhibitors have revolutionized the clinical management of patients with KRASG12C-mutant lung adenocarcinoma. However, patient exposure to these inhibitors leads to the rapid onset of resistance. In this study, we have used genetically engineered mice to compare the therapeutic efficacy and the emergence of tumor resistance between genetic ablation of mutant Kras expression and pharmacological inhibition of oncogenic KRAS activity. Whereas Kras ablation induces massive tumor regression and prevents the appearance of resistant cells in vivo, treatment of KrasG12C/Trp53-driven lung adenocarcinomas with sotorasib, a selective KRASG12C inhibitor, caused a limited antitumor response similar to that observed in the clinic, including the rapid onset of resistance. Unlike in human tumors, we did not observe mutations in components of the RAS-signaling pathways. Instead, sotorasib-resistant tumors displayed amplification of the mutant Kras allele and activation of xenobiotic metabolism pathways, suggesting that reduction of the on-target activity of KRASG12C inhibitors is the main mechanism responsible for the onset of resistance. In sum, our results suggest that resistance to KRAS inhibitors could be prevented by achieving a more robust inhibition of KRAS signaling mimicking the results obtained upon Kras ablation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsAnimalsMiceMutationOncogenesProto-Oncogene Proteins p21(ras)Signal Transduction

Stichwörter der Autor:innen

Drug therapyLung cancerOncogenesOncology

Substanzen

KRAS protein, humanProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Experimental Oncology Group, Molecular Oncology Program.
  • Bioinformatics Unit.
  • Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program.
  • Molecular Imaging Unit.
  • Flow Cytometry Unit.
  • Genomics Unit.

Förderung

  • H2020 European Research Council
  • Ministerio de Ciencia e Innovación
  • Comunidad de Madrid
  • CRIS Cancer Foundation
  • Fundación Científica Asociación Española Contra el Cáncer
  • Instituto de Salud Carlos III

Zitieren

APA

Salmón, M., Álvarez-Díaz, R., Fustero-Torre, C., Brehey, O., Lechuga, C. G., Sanclemente, M., Fernández-García, F., López-García, A., Martín-Guijarro, M. C., Rodríguez-Perales, S., Bousquet-Mur, E., Morales-Cacho, L., Mulero, F., Al-Shahrour, F., Martínez, L., Domínguez, O., Caleiras, E., Ortega, S., Guerra, C., …, & Barbacid, M. (2023). Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas. Journal of Clinical Investigation, 133(7). https://doi.org/10.1172/jci164413

Vancouver

Salmón M, Álvarez-Díaz R, Fustero-Torre C, Brehey O, Lechuga CG, Sanclemente M, et al. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas. Journal of Clinical Investigation. 2023;133(7). doi:10.1172/jci164413

BibTeX
@article{Salmn2023,
  author = {Salmón, Marina and Álvarez-Díaz, Ruth and Fustero-Torre, Coral and Brehey, Oksana and Lechuga, Carmen G and Sanclemente, Manuel and Fernández-García, Fernando and López-García, Alejandra and Martín-Guijarro, María Carmen and Rodríguez-Perales, Sandra and Bousquet-Mur, Emily and Morales-Cacho, Lucía and Mulero, Francisca and Al-Shahrour, Fátima and Martínez, Lola and Domínguez, Orlando and Caleiras, Eduardo and Ortega, Sagrario and Guerra, Carmen and Musteanu, Monica and Drosten, Matthias and Barbacid, Mariano},
  title = {Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {7},
  doi = {10.1172/jci164413}
}
Kostenlos starten →